LIVE WEBINAR: Thursday, January 6, 2022, 5:00 PM – 6:00 PM Eastern Time (ET)

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Breast Cancer

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Thursday, January 6th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Harold J Burstein, MD, PhD
Institute Physician, Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Additional faculty to be announced.

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Inc, Gilead Sciences Inc, Novartis and Seagen Inc.

Thursday, January 6, 2022
5:00 PM – 6:00 PM Eastern Time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • PART I: Current and Emerging Strategies for Localized Disease
  • PART II: Advances in the Care of Patients with Metastatic Breast Cancer

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate published research data to guide the selection and duration of neoadjuvant, adjuvant or extended-adjuvant therapy for patients with localized HER2-overexpressing breast cancer.
  • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, incorporating existing and recently approved anti-HER2 therapies.
  • Recognize common and rare side effects associated with novel anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
  • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive breast cancer.
  • Consider available clinical trial findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the potential role of these agents as neoadjuvant or adjuvant treatment.
  • Individualize the selection and sequencing of systemic therapy for patients with ER-positive metastatic breast cancer, considering age, menopausal status, prior treatment course, PIK3CA mutation status, comorbidities, symptomatology and extent and sites of disease.
  • Appreciate available Phase III data documenting the efficacy of adjuvant PARP inhibition for patients with high-risk localized HER2-negative breast cancer with BRCA mutations, and consider the potential role of this strategy in clinical practice.
  • Review published research evidence for the benefit of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for newly diagnosed high-risk localized or metastatic triple-negative breast cancer (TNBC), and use this information to recommend appropriate treatment for patients.
  • Evaluate published research findings guiding the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or those with TNBC who experience disease progression on front-line chemoimmunotherapy.
  • Appraise published efficacy and safety data with PARP inhibitors for patients with metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for localized and metastatic breast cancer.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Inc, Gilead Sciences Inc, Novartis and Seagen Inc.